What is a stock summary page? Click here for an overview.
Business Description
Century Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US15673T1007
Description
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.52 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.33 | |||||
| Debt-to-EBITDA | -0.48 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -3.88 | |||||
| Beneish M-Score | -2.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 20.4 | |||||
| 3-Year EPS without NRI Growth Rate | 19.1 | |||||
| 3-Year FCF Growth Rate | 30.3 | |||||
| 3-Year Book Growth Rate | -35.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.95 | |||||
| 9-Day RSI | 32.55 | |||||
| 14-Day RSI | 32.02 | |||||
| 3-1 Month Momentum % | -33.63 | |||||
| 6-1 Month Momentum % | -57.05 | |||||
| 12-1 Month Momentum % | -84.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | |||||
| Quick Ratio | 1.5 | |||||
| Cash Ratio | 1.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.6 | |||||
| Shareholder Yield % | -170.89 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2030.5 | |||||
| Net Margin % | -1920.61 | |||||
| FCF Margin % | -1683.44 | |||||
| ROE % | -67.2 | |||||
| ROA % | -33.89 | |||||
| ROIC % | -65.81 | |||||
| 3-Year ROIIC % | -66.45 | |||||
| ROC (Joel Greenblatt) % | -134.65 | |||||
| ROCE % | -37.48 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.29 | |||||
| PB Ratio | 0.29 | |||||
| Price-to-Tangible-Book | 0.37 | |||||
| EV-to-EBIT | 0.71 | |||||
| EV-to-EBITDA | 0.8 | |||||
| EV-to-Revenue | -13.46 | |||||
| EV-to-Forward-Revenue | 6.83 | |||||
| EV-to-FCF | 0.8 | |||||
| Price-to-GF-Value | 0.09 | |||||
| Price-to-Net-Current-Asset-Value | 18.5 | |||||
| Earnings Yield (Greenblatt) % | 140.85 | |||||
| FCF Yield % | -235.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IPSC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Century Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.59 | ||
| EPS (TTM) ($) | -1.63 | ||
| Beta | 2.15 | ||
| 3-Year Sharpe Ratio | -0.52 | ||
| 3-Year Sortino Ratio | -0.93 | ||
| Volatility % | 84.17 | ||
| 14-Day RSI | 32.02 | ||
| 14-Day ATR ($) | 0.056201 | ||
| 20-Day SMA ($) | 0.623335 | ||
| 12-1 Month Momentum % | -84.73 | ||
| 52-Week Range ($) | 0.5223 - 4.78 | ||
| Shares Outstanding (Mil) | 86.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Century Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Century Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Century Therapeutics Inc Frequently Asked Questions
What is Century Therapeutics Inc(IPSC)'s stock price today?
The current price of IPSC is $0.56. The 52 week high of IPSC is $4.78 and 52 week low is $0.52.
When is next earnings date of Century Therapeutics Inc(IPSC)?
The next earnings date of Century Therapeutics Inc(IPSC) is 2025-05-09 Est..
Does Century Therapeutics Inc(IPSC) pay dividends? If so, how much?
Century Therapeutics Inc(IPSC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers